An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine

Journal of Psychopharmacology

Volumn 24, Issue 6, 2010, Pages 817-828

  Wilkinson, J L ^a   Carroll, F I ^b   Bevins, R A ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Conditioned stimulus; Discriminative stimulus; Dopamine; Drug discrimination; Hydroxybupropion; Nicotinic acetylcholine receptors; Pavlovian conditioning; Zyban

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMFEBUTAMONE; DRUG METABOLITE; ETICLOPRIDE; NICOTINE; RADAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONDITIONING; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOPAMINERGIC ACTIVITY; DRUG MECHANISM; MALE; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING CESSATION; STIMULUS RESPONSE; TOBACCO DEPENDENCE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZAZEPINES; BUPROPION; DISCRIMINATION LEARNING; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1;

EID: 77952981053     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109102518     Document Type: Article

References (57)

1. Balster, RL (1988) Drugs as chemical stimuli. In: Colpaert, FC, Balster, RL (eds). Psychopharmacology Series 4: Transduction Mechanisms of Drug Stimuli. New York: Springer, pp. 3-11.
2. Bergman, J., Spealman, RD (1988) Behavioral effects of histamine H1 antagonist: comparison with other drugs and modification by haloperidol. J Pharmacol Exp Ther 245: 471-478.
3. Besheer, J., Jensen, HC, Bevins, RA (1999) Dopamine antagonism in a novel-object preference and a novel-object place conditioning preparation with rats. Behav Brain Res 103: 35-44.
4. Besheer, J., Palmatier, MI, Metschke, DM, Bevins, RA (2004) Nicotine as a signal for the presence or absence of sucrose reward: a Pavlovian drug appetitive conditioning preparation in rats. Psychopharmacology 172: 108-117.
5. Bevins, RA (2009) Altering the motivational function of nicotine through conditioning processes. In: Bevins, RA, Caggiula, AR (eds). The motivational impact of nicotine and its role in tobacco use: The 55th Nebraska Symposium on Motivation. NY: Springer, pp. 111-129.
6. Bevins, RA, Palmatier, MI (2004) Extending the role of associative learning processes in nicotine addiction. Behav Cogn Neurosci Rev 3: 143-158.
7. Bevins, RA, Besheer, J., Pickett, KS (2001) Nicotine-conditioned locomotor activity in rats: Dopaminergic and GABAergic influences on conditioned expression. Pharmacol Biochem Behav 68: 135-145.
8. Bevins, RA, Penrod, RD, Reichel, CM (2007) Nicotine does not produce state-dependent effects on learning in a Pavlovian appetitive goal tracking task with rats. Behav Brain Res 177: 134-341.
9. Bondarev, ML, Bondareva, TS, Young, R., Glennon, RA (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharm 474: 85-93.
10. Bouton, ME (2002) Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biol Psychiatry 52: 976-986.
11. Bruijnzeel, AW, Markou, A. (2003) Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse 50: 20-28.
12. Carboni, E., Imperato, A., Perezzani, L., Di Chiara, G. (1989) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653-661.
13. Centers for Disease Control and Prevention Cigarette Smoking Among Adults-United States, 2000. Morbidity and Mortality Weekly Report [serial online] 2002;51(29):642-645 [cited 2006 Nov 06]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5129a3.htm
14. Clark, MS (1969) Self-administered nicotine solutions preferred to placebo by the rat. B J Pharmacol 35: 367 P.
15. Conklin, CA, Tiffany, ST (2002) Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97: 155-167.
16. Cooper, BR, Hester, TJ, Maxwell, RA (1980) Behavioral and biochemical effects of the antidepressant bupropion (Welbutrin). Evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exper Therap 215: 127-134.
17. Cryan, JF, Bruijnzeel, AW, Skjei, KL, Markou, A. (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168: 347-358.
18. Damaj, MI, Carroll, FI, Eaton, JB, Navarro, HA, Blough, BE, Mirza, S., et al. (2004) Enantioselective effects of metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66: 675-682.
19. Dani, JA, De Biasi, M. (2001) Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70: 439-446.
20. Dani, JA, Heinemann, S. (1996) Molecular and cellular aspects of nicotine abuse. Neuron 16: 905-908.
21. Dwoskin, LP, Rauhut, AS, King-Pospisil, KA, Bardo, MT (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12: 178-207.
22. Fryer, JD, Lukas, RJ (1999) Noncompetitive functional inhibition at diverse human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288: 88-92.
23. Gonzales, D., Rennard, SI, Nides, M., Oncken, C., Azoulay, S., Billing, CB, et al. (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296: 47-55.
24. Hurt, RD, Sachs, DP, Glover, ED, Offord, KP, Johnston, JA, Dale, LC, et al. (1997) A comparison of sustained-release bupropion and placebo for smoking-cessation. N Engl J Med 337: 1195-1202.
25. Huston-Lyons, D., Kornetsky, C. (1992) Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol Biochem Behav 41: 755-759.
26. Jones, CN, Howard, JL, McBennett, ST (1980) Stimulus properties of antidepressants in the rat. Psychopharmacology 67: 111-118.
27. Jorenby, DE, Hays, JT, Rigotti, NA, Azoulay, S., Watsky, EJ, Williams, KE, et al. (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained release bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56-63.
28. Lamb, RJ, Griffiths, RR (1990) Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 102: 183-190.
29. Martin, P., Massol, J., Colin, JN, Lacomblez, L., Puech, AJ (1990) Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23: 187-194.
30. Mihalak, KB, Carroll, FI, Luetje, CW (2006) Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 70: 801-805.
31. Miller, DK, Sumithran, SP, Dwoskin, LP (2002) Bupropion inhibits nicotine-evoked [(3)H] overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exper Therap 302: 1113-1122.
32. Murray, JE, Bevins, RA (2007 a) The conditional stimulus effects of nicotine vary as a function of training dose. Behav Pharmacol 18: 707-716.
33. Murray, JE, Bevins, RA (2007 b) Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus. Eur J Pharmacol 561: 91-104.
34. National Institute on Drug Abuse (2006) Cigarettes and other tobacco products. NIDA Info Facts. Last accessed May 2007. Available from: www.drugabuse.gov/pdf/infofacts/Tobacco06
35. National Research Council (1996) Guide for the care and use of laboratory animals. Washington, DC: National Academy Press.
36. Nisell, M., Marcus, M., Nomikos, GG, Svensson, TH (1997) Differential effects of acute and chronic nicotine on dopamine output in the core and shell of the rat nucleus accumbens. J Neural Transmission 104: 1-10.
37. Nomikos, GC, Damsma, G., Wenkstern, D., Fibiger, HC (1992) Effect of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7: 7-14.
38. Ortmann, R. (1985) The conditioned place preference paradigm in rats: Effect of bupropion. Life Sci 37: 2021-2027.
39. Palmatier, MI, Bevins, RA (2002) Examination of GABAergic and dopaminergic compounds in the acquisition of nicotine-conditioned hyperactivity in rats. Neuropsychobiology 45: 87-94.
40. Pavlov, IP (1927) Conditioned reflexes: An investigation of the physiological activity of the cerebral cortex (G. V. Anrep, Trans.). London: Oxford University Press.
41. Rauhut, AS, Neugebauer, N., Dwoskin, LP, Bardo, MT (2003) Effect of bupropion on nicotine self-administration in rats. Psychopharmacology 169: 1-9.
42. Rotzinger, S., Bourin, M., Akimoto, Y., Coutts, RT, Baker, GB (1999) Metabolism of some "second" and "fourth" generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol 19: 427-442.
43. Rescorla, RA (1997) Spontaneous recovery after Pavlovian conditioning with multiple outcomes. Animal Learn Behav 25: 99-107.
44. Schoeder, DH (1983) Metabolism and kinetics of bupropion. J Clin Psychiatry 44: 79-81.
45. Shoaib, M. (1998) Is dopamine important in nicotine dependence ? J Physiol 92: 229-233.
46. Shoaib, M., Sidhpura, N., Shafait, S. (2003) Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 165: 405-412.
47. Slemmer, JE, Martin, BR, Damaj, MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295: 321-327.
48. Swan, GE, McAfee, T., Curry, SJ, Jack, LM, Javitz, H., Dacey, S., et al. (2003) Effectiveness of bupropion sustained release for smoking cessation in a health care setting. Arch Intern Med 163: 2337-2344.
49. Tella, SE, Ladenheim, B., Lud Cadet, J. (1997) Differential Regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281: 508-513.
50. Terry, P., Katz, JL (1997) Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats. Psychopharmacology 134: 201-212.
51. Wiley, JL, LaVecchia, KL, Martin, BR, Damaj, MI (2002) Nicotine-like discriminative stimulus effects of bupropion in rats. Exp Clin Psychopharmacol 10: 129-135.
52. Wilkinson, JL, Bevins, RA (2007) Bupropion hydrochloride produces conditioned hyperactivity in rats. Physiol Behav 90: 790-796.
53. Wilkinson, JL, Bevins, RA (2008) Intravenous nicotine conditions a place preference in rats using an unbiased design. Pharmacol Biochem Behav 88: 256-264.
54. Wilkinson, JL, Murray, JE, Li, C., Wiltgen, SM, Penrod, RD, Berg, SA, et al. (2006 a) Interoceptive Pavlovian conditioning with nicotine as the conditional stimulus varies as a function of number of conditioning trials and unpaired sucrose deliveries. Behav Pharmacol 17: 161-172.
55. Wilkinson, JL, Palmatier, MI, Bevins, RA (2006 b) Pre-exposure to nicotine alters subsequent locomotor stimulant effects of bupropion in rats. Nicotine Tob Res 184: 470-481.
56. Young, R., Glennon, RA (2002) Nicotine and bupropion share a similar discriminative stimulus effect. Eur J Pharmacol 443: 113-118.
57. Zocchi, A., Girlanda, E., Varnier, G., Sartori, I., Zanetti, L., Wildish, GA, et al. (2003) Dopamine responsiveness to drugs of abuse: A shell-core investigation in the nucleus accumbens in the mouse. Synapse 50: 293-302.